Replies to post #133639 on NanoViricides Inc. (NNVC)

[arvitar]

The Company has an accumulated deficit at March 31, 2017 of $72,570,721. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of March 31, 2017 the Company had cash and cash equivalents of $16,155,085.

p.9 http://ih.advfn.com/p.php?pid=nmona&article=74594460

[KMBJN]

Very nice results. Can't wait to see what this drug can do in humans.

I'm curious how quickly these drugs work, compared to acyclovir. I didn't see that in the poster. I think they only showed results at 6 days. Also, they treated with the various ShinglesCides before infecting the cells. I would have liked to have seen the effect of treatment after infection. If somehow they could show percent of infected cells that would have been great, too.

This cell culture is not a perfect system. If nanoviricides truly act only outside of cells, then it would appear these drugs are preventing virus from infecting the cells. In humans, the drugs would potentially act to prevent additional cells from being infected (spread to other skin cells and to other neurons). Ideally would start with a few infected cells in a dish and measure how well the drugs block infection of additional cells. Could take the infected cells, wash them, and add them to uninfected cells, then see how well the drug works to prevent infection in additional cells.

By the way, the "optimization problem" seems like it can be solved the way most other drug discovery is done, by screening lots of compounds - which NNVC did, and can continue to do.

Also, it's nice to see confirmation this was all done "in-house" by NNVC and AllExcel scientists (probably almost all by Friedrich).

I'm looking forward to some critical evaluation of this work, such as quibbling about what does "5 times better than acyclovir" really mean?

Overall it's a nice solid foundation of work.

[JG36]

So this poster session is about the cell culture work done in house by NNVC. We're still waiting for the SUNY results.